Listen "ASCO 2026 Plenary: RASolute-302"
Episode Synopsis
This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
More episodes of the podcast Two Onc Docs
Iron Overload 2026 UPDATE
17/08/2026
How to Approach a New Malignancy 101
03/08/2026
Tips for Heme/Onc Fellowship 2026
28/07/2026
DLBCL 2026 UPDATE
20/07/2026
Wellness in Oncology with Dr. Laura Vater
13/07/2026
ASCO 2026 Plenary: SARC-041
22/06/2026
ASCO Annual Meeting 2026 GU Recap
15/06/2026
ASCO Annual Meeting 2026 Preview
25/05/2026
Von Willebrand Disease (VWD) 2026 UPDATE
18/05/2026
